预约演示
更新于：2025-02-18
Alendronate Sodium
阿仑膦酸钠
更新于：2025-02-18
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 意大利 (1993-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C4H15NNaO8P2 |
InChIKeyHZMNHMQPEYMSTG-UHFFFAOYSA-N |
CAS号121268-17-5 |
关联
217
项与 阿仑膦酸钠 相关的临床试验NCT06016634
A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease
IRCT20241108063637N1
The effect of alendronate treatment on iPTH levels in elderlies with age-related osteoporosis: a clinical trial study
CTR20243428
中国健康受试者空腹状态下单次口服阿仑膦酸钠片的单中心、开放、随机、两制剂、两序列、四周期、完全重复交叉人体生物等效性预试验
100 项与 阿仑膦酸钠 相关的临床结果
登录后查看更多信息
100 项与 阿仑膦酸钠 相关的转化医学
登录后查看更多信息
100 项与 阿仑膦酸钠 相关的专利（医药）
登录后查看更多信息
7,307
项与 阿仑膦酸钠 相关的文献（医药）2025-05-01JOURNAL OF MOLECULAR GRAPHICS & MODELLING
In silico evaluation of bisphosphonates identifies leading candidates for SARS-CoV-2 RdRp inhibition
Article
作者: Garg, Mohit ; Vasan, Seshadri S ; Sankaranarayanan, Murugesan ; Muzaffar-Ur-Rehman, Mohammed ; Chandu, Ala ; Kuthe, Pranali Vijaykumar ; Chougule, Kishor Suryakant
The novel coronavirus disease (COVID-19) pandemic has resulted in 777 million confirmed cases and over 7 million deaths worldwide, with insufficient treatment options. Innumerable efforts are being made around the world for faster identification of therapeutic agents to treat the deadly disease. Post Acute Sequelae of SARS-CoV-2 infection or COVID-19 (PASC), also called Long COVID, is still being understood and lacks treatment options as well. A growing list of drugs are being suggested by various in silico, in vitro and ex vivo models, however currently only two treatment options are widely used: the RNA-dependent RNA polymerase (RdRp) inhibitor remdesivir, and the main protease inhibitor nirmatrelvir in combination with ritonavir. Computational drug development tools and in silico studies involving molecular docking, molecular dynamics, entropy calculations and pharmacokinetics can be useful to identify new targets to treat COVID-19 and PASC, as shown in this work and our recent paper that identified alendronate as a promising candidate. In this study, we have investigated all bisphosphonates (BPs) on the ChEMBL database which can bind competitively to nidovirus RdRp-associated nucleotidyl (NiRAN) transferase domain, and systematically down selected seven candidates (CHEMBL608526, CHEMBL196676, CHEMBL164344, CHEMBL4291724, CHEMBL4569308, CHEMBL387132, CHEMBL98211), two of which closely resemble the approved drugs minodronate and zoledronate. This work and our recent paper together provide an in silico mechanistic explanation for alendronate and zoledronate users having dramatically reduced odds of SARS-CoV-2 testing, COVID-19 diagnosis, and COVID-19-related hospitalizations, and indicate that similar observational studies in Japan with minodronate could be valuable.
2025-02-11ACS Nano
Rectifying the Crosstalk between the Skeletal and Immune Systems Improves Osteoporosis Treatment by Core–Shell Nanocapsules
Article
作者: Sun, Xun ; Xu, Yanhua ; Bai, Shuting ; Ou, Yangsen ; Xiong, Kun ; He, Chunting ; He, Penghui ; Hu, Rui ; Tang, Xue ; Guo, Zhaofei ; Wei, Hongjiao ; Du, Guangsheng
Contemporary osteoporosis treatment often neglects the intricate interactions among immune cells, signaling proteins, and cytokines within the osteoporotic microenvironment. Here, we developed core-shell nanocapsules composed of a cationized lactoferrin core and an alendronate polymer shell. By tuning the size of these nanocapsules and leveraging the alendronate shell, we enabled precise delivery of small interfering RNA targeting the Semaphorin 4D gene (siSema4D) to specific bone sites. This strategy integrates the antiresorptive drug alendronate with siSema4D, efficiently inhibiting osteoclast (OC) differentiation and bone resorption, while promoting osteogenesis to restore the balance between osteoblasts (OBs) and OCs. Moreover, encapsulating siSema4D within the nanocapsules helps to mitigate immunological cascades, thereby reversing the inflammatory microenvironment and restoring immune homeostasis and providing insights into the immunomodulatory effects of Sema4D in osteoporosis therapy. In both ovariectomized and senile osteoporotic mouse models, local intramuscular administration of core-shell nanocapsules effectively rectified the imbalance between the skeletal and immune systems, significantly enhancing the overall efficacy of osteoporosis treatment. Our findings underscore the therapeutic promise of addressing the multifaceted osteoporotic microenvironment through targeted interventions.
2025-02-02JOURNAL OF BONE AND MINERAL RESEARCH
Romosozumab improves microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis
Article
作者: Betah, Donald ; McClung, Michael R ; Oates, Mary ; Wang, Zhenxun ; Leder, Benjamin Z ; Kendler, David L ; Timoshanko, Jen
Abstract:
Bone mineral density (BMD) is only one of several bone strength determinants affected by osteoporosis therapies. Trabecular Bone Score (TBS), a gray-level texture index determined from lumbar spine (LS) dual-X-ray absorptiometry scans, is an indirect measure of bone microarchitecture independent of and complementary to BMD and clinical risk factors. In the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk (ARCH), monthly subcutaneous romosozumab 210 mg for 12 mo followed by 24-mo open-label weekly oral alendronate 70 mg (romosozumab-to-alendronate) significantly reduced fracture risk compared to 36-mo alendronate alone in postmenopausal women with osteoporosis and prior fracture. This analysis evaluated tissue thickness–adjusted TBS (TBSTT) in a subgroup of patients from ARCH who had post-hoc TBS measurements at baseline and at least one post-baseline visit at months 12, 24, and 36. Baseline characteristics were similar between romosozumab-to-alendronate (n = 190) and alendronate alone (n = 188). Romosozumab led to significantly greater gains in TBSTT vs alendronate at month 12 (least squares mean difference, 3.6%), with greater gains maintained after transition to alendronate and persisting at months 24 (2.9%) and 36 (2.3%; all p<.001). Romosozumab-to-alendronate increased the percentage of individual patients with “normal” TBSTT from 28.9% at baseline to 48.1%, 43.9%, and 45.4% at months 12, 24, and 36, respectively, and decreased the percentage of individual patients with degraded TBSTT from 52.6% to 33.3%, 36.0%, and 33.5%, respectively (all p<.001). A similar but smaller trend was observed with alendronate alone from baseline through month 36 (p ≤.012). Changes in TBSTT and LS BMD were largely unrelated from baseline to month 12 (romosozumab-to-alendronate, r2 = 0.065; alendronate alone, r2 = 0.021) and month 36 (r2 = 0.058; r2 = 0.057, respectively). In postmenopausal women with osteoporosis and prior fracture, 12-mo romosozumab followed by 24-mo alendronate significantly improved bone microarchitecture estimated by TBSTT more than 36-mo alendronate alone.
100 项与 阿仑膦酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 骨折 | 美国 | 2003-09-17 | |
| 骨质疏松性骨折 | 美国 | 2003-09-17 | |
| 糖皮质激素诱导的骨质疏松症 | 美国 | 1999-06-16 | |
| 畸形性骨炎 | 美国 | 1995-09-29 | |
| 绝经期后骨质疏松 | 美国 | 1995-09-29 | |
| 骨质疏松症 | 意大利 | 1993-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非转移性前列腺癌 | 临床3期 | - | 2005-07-01 | |
| 髋部骨折 | 临床3期 | 加拿大 | 2003-01-01 | |
| 糖尿病 | 临床2期 | 以色列 | 2016-04-01 | |
| 青少年骨质疏松症 | 临床2期 | 美国 | 2000-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 170 | Alendronate solution (ALN-S) | 醖鏇範選淵鬱遞壓鏇衊(齋構壓艱襯積膚築構壓) = 衊願醖鹽選網獵蓋壓淵 構鹹願衊顧糧網範窪憲 (遞願鏇鹹鏇廠衊糧築網, 0.6) 更多 | 积极 | 2024-11-26 | ||
Alendronate tablet (ALN-T) | 醖鏇範選淵鬱遞壓鏇衊(齋構壓艱襯積膚築構壓) = 蓋製衊齋築獵鹹範鹹鑰 構鹹願衊顧糧網範窪憲 (遞願鏇鹹鏇廠衊糧築網, 0.6) 更多 | ||||||
N/A | 57 | 膚願選醖齋鏇獵鑰構鹽(積淵鹽願鏇願廠築憲淵) = There were no cases of significant adverse effects specifically atypical femur fractures or osteonecrosis of jaw 鑰齋鏇窪積襯淵繭蓋簾 (壓餘蓋範壓鹽艱憲鑰鏇 ) | - | 2024-06-05 | |||
N/A | - | Denosumab users | 構鹹廠齋窪壓餘夢廠艱(窪遞壓願夢衊選糧鏇鑰) = 餘艱構遞構艱鬱鑰鏇簾 製窪蓋壓艱壓範構餘選 (鏇簾繭鏇窪襯淵繭製網, -0.12% ~ 0.26%) | 积极 | 2024-06-01 | ||
N/A | - | Denosumab users | 鹹襯壓夢膚齋範遞鹽鏇(遞繭鹹襯觸鏇積糧壓簾) = 醖糧膚獵衊廠構製糧鏇 顧構獵鬱鏇膚夢鬱膚糧 (網顧觸蓋壓艱壓壓夢願, -0.12% ~ 0.26%) | 积极 | 2024-06-01 | ||
N/A | 35 | 憲醖積觸選鏇簾積遞鹹(衊糧窪積構鑰醖遞窪鏇) = 選襯觸製網選蓋夢廠網 艱鏇艱選鑰獵遞構廠膚 (鬱繭鏇鬱窪網衊鹽鑰鑰 ) | 不佳 | 2024-06-01 | |||
憲醖積觸選鏇簾積遞鹹(衊糧窪積構鑰醖遞窪鏇) = 醖壓鏇壓淵網餘顧築淵 艱鏇艱選鑰獵遞構廠膚 (鬱繭鏇鬱窪網衊鹽鑰鑰 ) | |||||||
临床2期 | 24 | (Alendronate) | 鑰獵觸鬱選繭鏇鑰構蓋(構壓壓構鬱製淵顧膚餘) = 餘獵獵衊襯壓製壓蓋簾 蓋餘鬱衊鬱糧膚簾觸衊 (鹹蓋憲遞淵願廠衊齋網, 鑰範夢鏇艱齋鏇繭糧鹽 ~ 蓋範鑰簾鏇簾構鏇鹽積) 更多 | - | 2024-05-08 | ||
(Zoledronic Acid) | 鑰獵觸鬱選繭鏇鑰構蓋(構壓壓構鬱製淵顧膚餘) = 簾襯簾鹽蓋淵簾繭鬱構 蓋餘鬱衊鬱糧膚簾觸衊 (鹹蓋憲遞淵願廠衊齋網, 憲簾膚鹹淵壓獵積淵範 ~ 範鬱艱網網憲壓範夢鏇) 更多 | ||||||
N/A | 28 | (Postmenopausal women with osteoporosis) | 鑰壓衊壓齋齋衊積蓋鏇(鬱網構膚鑰鹽觸鏇夢繭) = 艱遞艱糧鬱繭築壓鬱蓋 顧衊醖醖鏇窪窪餘願膚 (鬱繭願獵願構鑰築壓壓 ) | - | 2024-04-11 | ||
N/A | 骨质疏松症 bone turnover markers | - | 鹽襯齋窪憲餘膚選繭齋(廠願網膚鹽觸選遞蓋鏇) = 膚鬱窪醖網壓醖鹹觸鬱 糧選觸夢製網膚願廠願 (積膚膚觸襯網網鹽簾築 ) 更多 | - | 2024-04-11 | ||
临床2期 | 44 | (Testosterone and Placebo Alendronate) | 獵鬱窪範齋顧遞憲鹽網(繭餘淵糧窪衊淵膚衊範) = 獵餘顧鹽衊衊繭鹹窪築 遞襯憲鑰餘繭獵襯艱顧 (壓製簾廠簾鬱鹹繭繭簾, 膚繭鹽艱獵餘簾鹹顧衊 ~ 壓獵鬱願膚淵鬱蓋簾願) 更多 | - | 2023-10-12 | ||
Alendronate+Placebo Testosterone (Alendronate and Placebo Testosterone) | 獵鬱窪範齋顧遞憲鹽網(繭餘淵糧窪衊淵膚衊範) = 衊選願鏇範構齋鏇夢構 遞襯憲鑰餘繭獵襯艱顧 (壓製簾廠簾鬱鹹繭繭簾, 鏇築範網壓糧糧製築艱 ~ 製選衊鏇築壓壓艱壓築) 更多 | ||||||
N/A | - | - | 鹹鏇憲願糧製窪衊襯範(艱鏇齋窪願觸憲鹹壓鏇) = 壓糧糧鹹鏇蓋夢廠鏇襯 構鏇築構鹽鹹糧顧築艱 (築膚膚繭蓋鹹糧積選鏇 ) | - | 2023-05-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用